Autres langues Soligenix, Inc.

Actions

SNGX

US8342235053

Temps réel estimé Cboe BZX Autres places de cotation 18:30:43 18/04/2024			Varia. 5j.	Varia. 1 janv.
0,454 ^USD	-10,98 %		+13,74 %	-41,61 %

03/04	Soligenix annonce un accord avec l'Agence européenne des médicaments sur la conception d'un deuxième essai confirmatoire contrôlé par placebo pour Hybryte ?	CI
15/03	Soligenix, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Soligenix Announces Pricing of $4.75 Million Public Offering	14:31
Sector Update: Health Care Stocks Softer Late Afternoon	15/04
Sector Update: Health Care Stocks Gain Monday Afternoon	15/04
Soligenix Shares Rise After Active Ingredient in MarVax Gets US FDA's Orphan Drug Designation	15/04
Soligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDA	15/04
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection	15/04
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection	11/04
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte? with the European Medicines Agency	03/04
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency	03/04
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results	15/03
Soligenix Announces Formation of Beh et s Disease Medical Advisory Board	09/02
Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board	08/02
Soligenix to Present at The Microcap Conference	25/01
FDA Grants Soligenix 'Fast Track' Designation for Dusquetide in the Treatment of Oral Lesions of Behcet's Disease	09/01
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease	08/01
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease	08/01
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis	04/01
Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis	04/01
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses	02/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Soligenix, Inc.

Actions

SNGX

US8342235053

Autres langues

Filtres